AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (previously presented): 8-(3-Pentylamino)-2-methyl-3-(2-chloro-4-methoxyphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidine methanesulfonate.

2. (previously presented): A crystal of 8-(3-pentylamino)-2-methyl-3-(2-chloro-4-methoxyphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidine methanesulfonate.

3. (previously presented): The crystal according to claim 2, which has X-ray powder diffraction spectrum shown in Fig 3.

4. (previously presented): The crystal according to claim 2, which has diffraction angle 2θ at 8.96, 12.70, 13.69, 14.98, 15.74, 16.38, 17.63, 18.98, 19.71, 20.49, 21.37, 22.26, 22.88, 23.76, 24.70, 25.79 and 26.57 on X-ray powder diffraction spectrum.

5. (previously presented): The crystal according to claim 2, which has infrared resonance spectrum shown in Fig. 4

6. (previously presented): The crystal according to claim 2, which has absorption of infrared resonance spectrum at 1652, 1595, 1549, 1220, 1168, 1141, 1115, 1034, 790, 766, 548, 533 and 522 cm^{-1}.

7. (previously presented): A process for the preparation of 8-(3-pentylamino)-2-methyl-3-(2-chloro-4-methoxyphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidine methanesulfonate, which comprises reacting 8-(3-pentylamino)-2-methyl-3-(2-chloro-4-methoxyphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidine with methanesulfonic acid.

8. (currently amended): A pharmaceutical composition comprising the compound ~~described in~~ according to claim 1 ~~as an active ingredient~~ and a pharmaceutically acceptable carrier.

9. (currently amended): ~~A~~The pharmaceutical composition comprising 1% or more of ~~a~~the crystal according to claim 2, ~~as an active ingredient, described in claim 2~~ and a pharmaceutically acceptable carrier.

10. (canceled).

11. (currently amended): A method of treating a mammal suffering from a disease resulting from elevated activity of Corticotropin Releasing Factor (CRF) comprising administrating to said mammal a therapeutically effective amount of ~~The~~the ~~pharmaceutical composition~~compound according to claim ~~8~~1~~, which is a prevention and/or treatment agent of a CRF mediated disease~~.

12. (currently amended): The ~~pharmaceutical composition according to~~ method of claim 11, wherein ~~the CRF-mediated~~ said disease resulting from elevated activity of Corticotropin Releasing Factor (CRF) is a neuropsychiatric disorder or a digestive system disease.

13. (currently amended): The ~~pharmaceutical composition according to~~ method of claim 12, wherein the neuropsychiatric disorder is a mood disorder, an anxiety disorder, a stress related disorder, an eating disorder, a symptom by psychotomimetic drug use and dependence, an organic mental disorder, schizophrenia or an attention-deficit hyperactivity disorder.

14. (currently amended): The ~~pharmaceutical composition according to~~ method of claim 12, wherein the digestive system disease is an irritable bowel syndrome or a stress-induced gastrointestinal disturbance.

15. (currently amended): The ~~pharmaceutical composition according to~~ method of claim 13, wherein the mood disorder is depression, single episode depression, recurrent depression, postpartum depression, child abuse induced depression, bipolar affective disorder or premenstrual dysphonic disorder.

16-19. (canceled).

20. (currently amended) A method for antagonizing the activity of ~~CRF~~Corticotropin Releasing Factor (CRF) in a mammal, ~~which comprises~~ comprising administering to said mammal an effective amount of ~~8-(3-Pentylamino)-2-methyl-3-(2-chloro-4-methoxyphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidine methanesulfonate to mammals~~the compound according to claim 1.

21-23. (canceled).

24. (new): 8-(3-Pentylamino)-2-methyl-3-(2-chloro-4-rnethoxyphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidine methanesulfonate which is superior in thermal stability.